Literature DB >> 9058690

Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells.

C A Akdis1, T Blesken, M Akdis, S S Alkan, B Wüthrich, C H Heusser, K Blaser.   

Abstract

Investigations on the mechanisms of IgE regulation in vitro have been conducted thus far in systems that allow the synthesis of total rather than specific IgE. To study the regulatory prerequisites of antigen-specific IgE antibody production, we have established a culture system that allows the generation of bee venom phospholipase A2-specific IgE and IgG4 antibodies. Allergen-specific IgE was induced by simultaneously activating T cells and B cells specifically with allergen and polyclonally with anti-CD2 and soluble CD40 ligand in the presence of IL-4. Additional stimulation of T cells through the CD2 activation pathway by two different anti-CD2 monoclonal antibodies enhanced both the allergen-specific and the total IgE and IgG4 responses. An optimal amount of allergen (0.1 ng/ml) resulted in the induction of both allergen-specific IgE and IgG4 antibodies. Higher antigen doses reduced allergen-specific antibodies and enhanced total isotype production. This differential regulation of allergen-specific and total isotypes reflects different allergen dose-dependent mechanisms in specific and polyclonal activation of T and B cells. Although both isotypes require IL-4 for initial induction, opposite regulatory effects by T cells were observed for IgE and IgG4 antibody expression. In peripheral blood mononuclear cell cultures stimulated with soluble CD40 ligand, IL-4, and phospholipase A2, stimulation of T cells with higher amounts of anti-CD2 enhanced IgG4 in parallel to increased IL-2 and interferon-gamma secretion but inhibited IgE synthesis. These results provide evidence for differential regulation of allergen-specific and total IgE and IgG4 by antigen concentration and demonstrate the pivotal role of T cells controlling the synthesis of the IgE and IgG4 antibody isotypes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058690     DOI: 10.1016/s0091-6749(97)70052-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  TGF-beta-mediated control of allergen-specific T-cell responses.

Authors:  Carsten B Schmidt-Weber; Steffen Kunzmann; Kurt Blaser
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

2.  In vitro production of IgG4 by peripheral blood mononuclear cells (PBMC): the contribution of committed B cells.

Authors:  B A de Boer; Y C Kruize; M Yazdanbakhsh
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 3.  [Immunological principles of IgG4 related diseases].

Authors:  T Witte
Journal:  Radiologe       Date:  2016-12       Impact factor: 0.635

Review 4.  Mechanisms of interleukin-10-mediated immune suppression.

Authors:  C A Akdis; K Blaser
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

Review 5.  [Immunological principles of IgG4 related diseases].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

6.  Different natural killer (NK) receptor expression and immunoglobulin E (IgE) regulation by NK1 and NK2 cells.

Authors:  E Aktas; M Akdis; S Bilgic; R Disch; C S Falk; K Blaser; C Akdis; G Deniz
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 7.  The immunology of the allergy epidemic and the hygiene hypothesis.

Authors:  Bart N Lambrecht; Hamida Hammad
Journal:  Nat Immunol       Date:  2017-09-19       Impact factor: 25.606

8.  Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1.

Authors:  M Satoh; H Toma; Y Sato; M Takara; Y Shiroma; S Kiyuna; K Hirayama
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

9.  Tracking antigen-specific T-cells during clinical tolerance induction in humans.

Authors:  Aamir Aslam; Hsien Chan; David A Warrell; Siraj Misbah; Graham S Ogg
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

10.  Role of interleukin 10 in specific immunotherapy.

Authors:  C A Akdis; T Blesken; M Akdis; B Wüthrich; K Blaser
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.